No Data
No Data
IceCure Medical Announces Meeting With Leadership Of The U.S. Food And Drug Administration's Center For Devices And Radiological Health Regarding The Company's De Novo Marketing Authorization Request For Prosense In The Treatment of Early-Stage Low...
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Maintains Target Price $3
Icecure Medical's Growth Potential Highlighted by Clinical Progress and Strategic Financial Position
H.C. Wainwright Maintains Icecure Medical(ICCM.US) With Buy Rating, Maintains Target Price $2.5
IceCure Medical Full Year 2024 Earnings: Misses Expectations
Express News | HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $2.5 Price Target